Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.51, $0.22 better than the analyst estimate of $0.29. Revenue for the quarter came in at $80.7 million versus the consensus estimate of $80.92 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.